A New World of CLL Therapies

How have chronic lymphocytic leukemia (CLL) treatments evolved over time? Is there a new world of treatment options? Dr. Ian Flinn, a CLL expert from Tennessee Oncology, and Nurse Practitioner Camille Ballance, answer those questions as they share the latest news and updates with Patient Power Co-Founders Andrew and Esther Schorr.

Watch as they discuss the shift from traditional treatment approaches like FCR chemotherapy to targeted therapies and time-limited therapies. They also share what new topics researchers are working on now to advance CLL therapies for the future.

This program is sponsored by AbbVie, Inc., Genentech, Inc. and Adaptive Biotechnologies. These organizations have no editorial control. It is produced by Patient Power in partnership with Tennessee Oncology, Bag It, and CLL Society. Patient Power is solely responsible for program content.

Key Takeaways

  • The next wave of clinical trials is looking at time-limited therapy, with a goal of getting the patient into remission and then stopping treatment.
  • BTK inhibitors cut off cell signaling, causing cancer cells to die. When combined with monoclonal antibodies, they’re even more effective.
  • Other areas of research include new BTK inhibitors to address drug resistance and improving CAR T-cell therapy.
This article was originally published April 24, 2020 and most recently updated September 15, 2020.
© 2024 HealthCentral LLC. All rights reserved.

More on Chronic Lymphocytic Leukemia